Teva’s Copaxone
Natco Pharma gained apiece to hit the upper circuit limit of 20% on the back of USFDA approving marketing partner Mylan’s application for generic version of Teva’s Copaxone that is…
Natco Pharma gained apiece to hit the upper circuit limit of 20% on the back of USFDA approving marketing partner Mylan’s application for generic version of Teva’s Copaxone that is…